Photo by nci from unsplash
3584Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-fusion+ no... Click to show full abstract
3584Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-fusion+ no...
Keywords:
selpercatinib loxo;
ret fusion;
loxo 292;
292 patients
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!